• 61.5% tumour reduction over 28 days, outperforming unmodified NK-EVs
• 100% survival rate in mice treated with CAR-NK-EVs
• Excellent safety profile with no observable adverse effects

INOVIQ Limited (ASX: IIQ) has announced positive in vivo proof-of-concept data demonstrating the therapeutic potential of its proprietary EGFR-targeted chimeric antigen receptor (CAR)-Natural Killer (NK)-extracellular vesicles (EVs or exosomes) in a triple-negative breast cancer (TNBC) mouse model. The in vivo study, conducted by GemPharmatech Co Ltd, evaluated the efficacy, safety and biodistribution of INOVIQ's CAR-NK-EV candidate compared with unmodified NK-EVs and vehicle controls. Bioluminescence imaging over 28 days showed that CAR-NK-EVs achieved excellent antitumor efficacy, reducing tumour burden by 61.5% compared to 24.5% for unmodified NK-EVs (p < 0.05). All mice treated with CAR-NK-EVs survived the 28-day study period (100%), versus 83.3% for unmodified NK-EVs and 66.7% for vehicle controls. CAR-NK-EV treatment was well tolerated, with stable body weight and no observable adverse effects, supporting a favourable preliminary safety profile for repeat dosing. Biodistribution analysis showed significantly reduced non-specific liver accumulation of CAR-NK-EVs compared to unmodified NK-EVs (p < 0.05), confirming superior tumour targeting specificity. INOVIQ has filed a new provisional patent application covering innovations in precision CAR-targeting and EV purification, further strengthening its intellectual property portfolio and protecting the core CAR-EV technology.

INOVIQ is accelerating preclinical and manufacturing development of its CAR-EV platform, with additional data readouts expected in 2026, supporting the path toward first-in-human studies in 2028 and value creation for patients, clinicians and shareholders.